Xiao Jian Zhou

Summary

Affiliation: Idenix Pharmaceuticals
Country: USA

Publications

  1. pmc Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:1739-46. 2009
  2. pmc Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 55:76-81. 2011
  3. doi request reprint Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:1408-16. 2009
  4. pmc Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 50:874-9. 2006
  5. pmc Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1721-6. 2006
  6. pmc Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2309-15. 2006
  7. ncbi request reprint Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    J Clin Pharmacol 46:275-81. 2006
  8. pmc Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 51:4231-5. 2007
  9. pmc Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor
    Steve Piscitelli
    Infectious Diseases MDC, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Clin Pharmacol 74:336-45. 2012
  10. doi request reprint Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:725-34. 2009

Collaborators

Detail Information

Publications10

  1. pmc Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:1739-46. 2009
    ..These favorable safety and pharmacokinetic results support further clinical studies with patients with HIV-1 infection by the use of a QD regimen...
  2. pmc Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 55:76-81. 2011
    ..All AEs were mild to moderate and resolved at the end of study. The favorable safety and pharmacokinetic profiles support further clinical evaluation of IDX184 in HCV-infected patients...
  3. doi request reprint Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:1408-16. 2009
    ..IDX899 has been selected based on these initial pharmacokinetic assessments and other criteria as the candidate for further clinical development...
  4. pmc Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 50:874-9. 2006
    ....
  5. pmc Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1721-6. 2006
    ....
  6. pmc Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2309-15. 2006
    ..The results from these studies provide pharmacologic support for combination therapy or therapy switching involving telbivudine, lamivudine, and adefovir dipivoxil for the treatment of chronic hepatitis B virus infection...
  7. ncbi request reprint Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    J Clin Pharmacol 46:275-81. 2006
    ..Results from this study indicated that the absorption of telbivudine was not affected by a high-fat/high-calorie meal; telbivudine can therefore be administered orally with no regard to the timing of meals...
  8. pmc Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 51:4231-5. 2007
    ....
  9. pmc Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor
    Steve Piscitelli
    Infectious Diseases MDC, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Clin Pharmacol 74:336-45. 2012
    ....
  10. doi request reprint Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:725-34. 2009
    ....